Effects of Pulmonary Hypertension on Outcomes After MVR for Rheumatic Mitral Stenosis - Pulmonology Advisor
Effects of Pulmonary Hypertension on Outcomes After MVR for Rheumatic Mitral Stenosis - Pulmonology Advisor |
Posted: 08 Aug 2019 03:00 AM PDT For patients with rheumatic mitral stenosis and pulmonary hypertension (PH) who undergo mitral valve replacement (MVR), proper control of systolic pulmonary arterial pressure (sPAP) and right ventricular systolic pressure (RVSP) may help prevent tricuspid regurgitation progression, according to study results published in the Annals of Thoracic Surgery. The aim of this retrospective study was to assess the effect of PH on long-term survival and late-onset tricuspid regurgitation in patients with rheumatic mitral stenosis who underwent a MVR. Patients were categorized into either a non-PH cohort with a sPAP ≤50 mm Hg or a PH cohort with a sPAP >50 mm Hg. Preoperative measurements of systolic, diastolic, and mean arterial pressure were taken after general anesthesia was administered, and a postoperative measurement of pulmonary arterial pressure was taken 48 hours after surgery. Echocardiography was completed preoperatively, postoperatively, and ≥6 months after discharge. Tricuspid regurgitation was visualized using a Doppler technique and categorized as none, mild, moderate, and severe. Patients were followed for 9.6±4 years. Of the 394 patients included in this study, 322 were categorized into the non-PH cohort and 72 were categorized into the PH cohort. These 2 cohorts differed on mean diastolic pressure gradient, RVSP, tricuspid regurgitation velocity, and systolic, diastolic and mean pulmonary arterial pressure at baseline (P <.001, for all). Changes from preoperative to postoperative measurements and postoperative measurements for RVSP and pulmonary arterial pressure were significantly higher in the PH cohort when compared with the non-PH cohort (P <.001, for all). At late follow-up, 23.8% of patients in the non-PH cohort and 29.9% of the patients in the PH cohort experienced tricuspid regurgitation progression. The 10-year survival rate was higher in the non-PH cohort, (90.7% vs 79.7%; P =.043), and the 10-year rate of freedom from tricuspid regurgitation was higher in patients with sPAP reductions (P =.003) and RVSP reductions (P <.001). Cox multivariate analysis indicated that a substantial reduction after surgery in sPAP (hazard ratio [HR] 0.966; 95% CI, 0.942-0.991; P =.008) and RVSP (HR 0.973; 95% CI, 0.960-0.986; P <.001) was found to prevent tricuspid regurgitation progression. Limitations of this study include potential selection or heterogeneity bias because of the nonrandomized, retrospective study design, the limited number of patients in the PH cohort, the lack of preoperative pulmonary arterial pressures collected, and not accounting for preoperative symptoms of right heart failure or postoperative vasodilator medications. The researchers concluded that "[a]lthough concomitant PH at MVR is associated with poor long-term survival, adequate sPAP and RVSP reduction can prevent [tricuspid regurgitation] progression even in patients with severe PH preoperatively." Reference Kim DJ, Lee S, Joo HC, et al. Effect of pulmonary hypertension on clinical outcomes in patients with rheumatic mitral stenosis [published online June 20, 2019]. Ann Thorac Surg. doi:10.1016/j.athoracsur.2019.05.077 This article originally appeared on The Cardiology Advisor | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Gossamer Bio Announces Second Quarter 2019 Financial Results - BioSpace Posted: 08 Aug 2019 01:05 PM PDT Aug. 8, 2019 20:05 UTC
– Five active clinical trials across four clinical programs, with data readouts for all four programs expected in 2020 – – Company to host conference call today at 4:30 p.m. ET – SAN DIEGO--(BUSINESS WIRE)-- Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology, today announced its financial results for the quarter ended June 30, 2019 and provided a corporate update. "Over the last several months, we have made significant progress advancing our diversified development portfolio, with five clinical trials now active," said Sheila Gujrathi, M.D., Co-Founder and Chief Executive Officer of Gossamer. "We are poised for a steady cadence of data readouts throughout 2020. Supported by a strong balance sheet and our experienced and growing team, we are well positioned to advance toward our goal of becoming an industry leader in immunology, inflammation and oncology." Pipeline Updates GB001: Oral DP2 Antagonist for Asthma and Allergic Disease
GB002: Inhaled PDGFR Inhibitor for Pulmonary Arterial Hypertension (PAH)
GB004: Oral HIF-1α Stabilizer for Inflammatory Bowel Disease
GB1275: Oral CD11b Modulator for Oncology Indications
Financial Results for Quarter Ended June 30, 2019
Conference Call and Webcast Gossamer's management team will host a conference call and live audio webcast at 4:30 p.m. ET today, Thursday, Aug. 8, 2019, to discuss its second quarter 2019 financial results and provide a corporate update. The live audio webcast may be accessed through the Events/Presentations page in the Investors section of the Company's website at www.gossamerbio.com. Alternatively, the conference call may be accessed through the following: Conference ID: 1393207 A replay of the audio webcast will be available for 30 days on the Investors section of the Company's website, www.gossamerbio.com. About Gossamer Bio Gossamer Bio is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology. Its goal is to be an industry leader in each of these therapeutic areas and to enhance and extend the lives of patients suffering from such diseases. Forward-Looking Statements Gossamer cautions you that statements contained in this press release regarding matters that are not historical facts are forward-looking statements. These statements are based on the Company's current beliefs and expectations. Such forward-looking statements include, but are not limited to, statements regarding the anticipated timing of initiation and enrollment of clinical trials for our product candidates; plans to rapidly advance our product candidates; expectations on the timing of data readouts from our clinical studies; the potential clinical benefits of our product candidates; the indications we intend to pursue and our related business strategies; the expected timeframe for funding our operating plan with current cash, cash equivalents and marketable securities; and access to the Company's senior debt facility. The inclusion of forward-looking statements should not be regarded as a representation by Gossamer that any of its plans will be achieved. Actual results may differ from those set forth in this press release due to the risks and uncertainties inherent in Gossamer's business, including, without limitation: potential delays in the commencement, enrollment and completion of clinical trials; the Company's dependence on third parties in connection with product manufacturing, research and preclinical and clinical testing; the success of Gossamer's clinical trials and preclinical studies for its product candidates; regulatory developments in the United States and foreign countries; unexpected adverse side effects or inadequate efficacy of the Company's product candidates that may limit their development, regulatory approval and/or commercialization, or may result in recalls or product liability claims; Gossamer's ability to obtain and maintain intellectual property protection for its product candidates; Gossamer's ability to comply with its obligations in the agreements under which it licenses intellectual property rights from third parties; the risk that the funding under the new senior debt facility may not be completed on the timeframe Gossamer expects, or at all, including as a result of Gossamer's failure to meet the conditions required for such funding or failure to comply with the affirmative and negative covenants under the credit facility; and other risks described in the Company's prior press releases and the Company's filings with the Securities and Exchange Commission (SEC), including under the heading "Risk Factors" in the Company's annual report on Form 10-K and any subsequent filings with the SEC. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and Gossamer undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement, which is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190808005764/en/ |
You are subscribed to email updates from "mild pulmonary hypertension" - Google News. To stop receiving these emails, you may unsubscribe now. | Email delivery powered by Google |
Google, 1600 Amphitheatre Parkway, Mountain View, CA 94043, United States |
Comments
Post a Comment